Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISUALIZE 2: Abenacianine in Lung Cancer Surgery
NCT07499674Phase 3Recruiting
- Sponsor
- Vergent Bioscience
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of abenacianine in lung cancer and lung metastases (LM) (2 arms), sponsored by Vergent Bioscience. Primary endpoint: Clinically Significant Event. Started Mar 2026; status: recruiting.
02
Drugs
abenacianine
03
Conditions
lung cancerlung metastases (LM)
Beyond the preview
Go deeper on NCT07499674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499674.